190 related articles for article (PubMed ID: 24462732)
1. Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer.
Harter P; Beutel B; Alesina PF; Lorenz D; Boergers A; Heitz F; Hils R; Kurzeder C; Traut A; du Bois A
Gynecol Oncol; 2014 Mar; 132(3):537-41. PubMed ID: 24462732
[TBL] [Abstract][Full Text] [Related]
2. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
Harter P; du Bois A; Hahmann M; Hasenburg A; Burges A; Loibl S; Gropp M; Huober J; Fink D; Schröder W; Muenstedt K; Schmalfeldt B; Emons G; Pfisterer J; Wollschlaeger K; Meerpohl HG; Breitbach GP; Tanner B; Sehouli J; ;
Ann Surg Oncol; 2006 Dec; 13(12):1702-10. PubMed ID: 17009163
[TBL] [Abstract][Full Text] [Related]
3. AGO Score As a Predictor of Surgical Outcome at Secondary Cytoreduction in Patients with Ovarian Cancer.
Muallem MZ; Gasimli K; Richter R; Almuheimid J; Nasser S; Braicu EI; Sehouli J
Anticancer Res; 2015 Jun; 35(6):3423-9. PubMed ID: 26026105
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
[TBL] [Abstract][Full Text] [Related]
5. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of PET-CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer.
Lenhard SM; Burges A; Johnson TR; Kirschenhofer A; Bruns C; Linke R; Friese K
Eur J Obstet Gynecol Reprod Biol; 2008 Oct; 140(2):263-8. PubMed ID: 18614272
[TBL] [Abstract][Full Text] [Related]
7. Performance of AGO score for secondary cytoreduction in a high-volume U.S. center.
Janco JM; Kumar A; Weaver AL; McGree ME; Cliby WA
Gynecol Oncol; 2016 Apr; 141(1):140-7. PubMed ID: 26836496
[TBL] [Abstract][Full Text] [Related]
8. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).
du Bois A; Reuss A; Pujade-Lauraine E; Harter P; Ray-Coquard I; Pfisterer J
Cancer; 2009 Mar; 115(6):1234-44. PubMed ID: 19189349
[TBL] [Abstract][Full Text] [Related]
9. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
[TBL] [Abstract][Full Text] [Related]
10. External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer.
van de Laar R; Massuger LF; Van Gorp T; IntHout J; Zusterzeel PL; Kruitwagen RF
Gynecol Oncol; 2015 May; 137(2):210-5. PubMed ID: 25677063
[TBL] [Abstract][Full Text] [Related]
11. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A
Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986
[TBL] [Abstract][Full Text] [Related]
12. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis.
Harter P; Hahmann M; Lueck HJ; Poelcher M; Wimberger P; Ortmann O; Canzler U; Richter B; Wagner U; Hasenburg A; Burges A; Loibl S; Meier W; Huober J; Fink D; Schroeder W; Muenstedt K; Schmalfeldt B; Emons G; du Bois A
Ann Surg Oncol; 2009 May; 16(5):1324-30. PubMed ID: 19225844
[TBL] [Abstract][Full Text] [Related]
13. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
[TBL] [Abstract][Full Text] [Related]
14. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
[TBL] [Abstract][Full Text] [Related]
15. A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses.
Bogani G; Tagliabue E; Signorelli M; Ditto A; Martinelli F; Chiappa V; Mosca L; Sabatucci I; Leone Roberti Maggiore U; Lorusso D; Raspagliesi F
J Gynecol Oncol; 2018 May; 29(3):e40. PubMed ID: 29533023
[TBL] [Abstract][Full Text] [Related]
16. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.
Harter P; Sehouli J; Reuss A; Hasenburg A; Scambia G; Cibula D; Mahner S; Vergote I; Reinthaller A; Burges A; Hanker L; Pölcher M; Kurzeder C; Canzler U; Petry KU; Obermair A; Petru E; Schmalfeldt B; Lorusso D; du Bois A
Int J Gynecol Cancer; 2011 Feb; 21(2):289-95. PubMed ID: 21270612
[TBL] [Abstract][Full Text] [Related]
17. Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Hoppenau B; du Bois A;
Gynecol Oncol; 2006 Feb; 100(2):300-7. PubMed ID: 16199079
[TBL] [Abstract][Full Text] [Related]
18. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
Chi DS; McCaughty K; Diaz JP; Huh J; Schwabenbauer S; Hummer AJ; Venkatraman ES; Aghajanian C; Sonoda Y; Abu-Rustum NR; Barakat RR
Cancer; 2006 May; 106(9):1933-9. PubMed ID: 16572412
[TBL] [Abstract][Full Text] [Related]
19. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
Santillan A; Karam AK; Li AJ; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Bristow RE
Gynecol Oncol; 2007 Mar; 104(3):686-90. PubMed ID: 17141302
[TBL] [Abstract][Full Text] [Related]
20. Recurrent micropapillary serous ovarian carcinoma.
Bristow RE; Gossett DR; Shook DR; Zahurak ML; Tomacruz RS; Armstrong DK; Montz FJ
Cancer; 2002 Aug; 95(4):791-800. PubMed ID: 12209723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
